jose r. berrezueta, md, Ph.D.
Dr. Berrezueta has done extensive work into the effects of nitroglycerin in multiple medical applications. His 1996 study in the journal of Pain was the first of its kind to assess the efficacy of topical nitroglycerin in acute tendonitis, focusing on supraspinatus tendonitis. He has also done other studies looking specifically at the analgesic and anti-inflammatory actions of nitroglycerin and its efficacy in other conditions, such as thrombophlebitis peripheral atherosclerosis. Dr. Berrezueta is Professor of Cardiology at the Universitary Hospital Marqués de Valdecilla in Santander.

Dr. Berrezueta graduated with a medical degree and doctoral degree from the University of Salamanca in 1970 and 1976 respectively. His initial training was as a cardiology registrar in Hospital Puerta de Hierro in Madrid from 1971 to 1973, and then at the National Institute of Cardiology of Mexico, now the Ignacio Chavez Institute for Heart Disease, in 1974. As a Visiting Professor in the Wellcome laboratories of London, under the scientific direction of nitric oxide pioneer Salvador Moncada, Dr. Berrezueta conducted research on nitric oxide’s anti-inflammatory and analgesic effects. Dr. Berrezueta’s contribution to science and his clinical efforts have been recently honored with an entry in the Royal Academy of Medicine.

ronald m. burch, md, Ph.D.
Dr Burch co-founded AlgoRx Pharmaceuticals, Inc. in 2001, and served as President until 2004 and as Chief Executive Officer since inception. A venture-backed pharmaceutical company focused on developing and commercializing a diversified portfolio of pharmaceutical product candidates to address pain, with three product candidates in development in four clinical programs and one preclinical program, the company was merged with Corgentech Inc. (Nasdaq: CGTK) in September, 2005.

Prior to joining AlgoRx, Dr Burch was employed at Purdue Pharma, a privately held pharmaceutical company, from 1995 until 1997, serving in a number of managerial positions, including Vice President, Scientific Evaluations and Immunotherapeutics and Project Manager and Medical Safety Officer for several pain development programs. From 1993 to 1995, Dr Burch served as Director, Pharmacology at Zeneca Pharmaceuticals, a pharmaceutical company. In 1992, Dr Burch served as Director, Immunology and Bone Metabolism at Rhone Poulenc Rorer, a global pharmaceutical company, and as Director, Pain and Inflammation at Nova Pharmaceutical Corp., a pharmaceutical company. From 1987 to 1991, Dr Burch served in various capacities at Nova Pharmaceutical, including as Director, Pain and Inflammation, Research Technology. Dr. Burch obtained a PhD in Pharmacology and MD from the Medical University of South Carolina, and served as a Medical Staff Fellow at the National Institute of Health.

bruce m gans, md
Bruce M. Gans, MD is Chief Medical Officer for the Kessler Institute for Rehabilitation, based in West Orange, New Jersey. Kessler is one of the nation's leading providers of comprehensive physical medicine and rehabilitation services. Dr. Gans is responsible for physician practices, academic affairs, and clinical quality for all in- and out-patient programs and services. He holds an appointment as Professor of Physical Medicine and Rehabilitation at the UMDNJ-New Jersey Medical School.

His previous appointments include Chairman of the Departments of Physical Medicine and Rehabilitation at Long Island Jewish Medical Center and North Shore University Hospital, and Professorships at the Albert Einstein College of Medicine of Yeshiva University and Wayne State University School of Medicine. He is currently serving as the President of the American Academy of Physical Medicine and Rehabilitation. He has been honored with recognition in “The Best Doctors in America,” and has received the AHA’s prestigious Brent England Award for Excellence in Rehabilitation Management.

Dr. Gans received his MD degree from the University of Pennsylvania School of Medicine in Philadelphia and an MS in Biomedical Electronic Engineering from the Moore School of Engineering at the University of Pennsylvania. He also holds an MS degree form the University of Washington. He served his medical internship at the Philadelphia General Hospital and residency in Physical Medicine & Rehabilitation at the University of Washington, Seattle. Dr. Gans received his BS degree in electrical engineering from Union College, Schenectady, New York.

frank kochinke, Ph.D.
Dr. Kochinke is President of EntrePreneurial Solutions, a San Jose-based company which provides scientific, technological and regulatory services in product development. Dr. Kochinke’s primary expertise is the development of innovative and proprietary controlled-release drug delivery systems. Dr. Kochinke has authored or co-authored 31 papers, 12 of which focused on controlled-release drug delivery systems. He holds 12 patents of which 11 are issued or allowed, and of which six are directly related to transdermal drug delivery.

Following a Ph.D. in Chemical Engineering at Technische Universität, Berlin, Dr. Kochinke was appointed a Senior Research Scientist at Membrane Technology & Research based in Menlo Park, CA. His role involved research, development and fabrication of novel controlled drug delivery systems. Dr. Kochinke then moved to Pharmetrix Corporation where, as Director of Research during 1988-1993, he instituted and directed an aggressive research program focusing on the development of innovative and new transdermal products. After spending three years at Oculex Pharmaceuticals as Director of Research and Development looking at intraocular drug delivery systems, Dr. Kochinke returned to Pharmetrix Corp for a further four years to assist development of a non-invasive glucose monitoring system and several transdermal and dermal products.

george a. c. murrell, md, Ph.D.
George Murrell is the inventor of Cure Therapeutics’ core intellectual property due to his pioneering work exploring the role of nitric oxide in wound healing. Notably, Dr. Murrell led clinical studies applying low-dose transdermal nitroglycerin patches to chronic tendinopathies in Achilles, supraspinatus tendons, and lateral epicondylitis (tennis elbow).

Dr. Murrell obtained his MBBS from Adelaide University and was the 1984 South Australian Rhodes Scholar. At Oxford he completed a DPhil (Ph.D.) thesis on Dupuytren's Contracture and was awarded the Royal College of Surgeons Arris and Gale medal for this work. Dr. Murrell completed his orthopedic training at Duke University and a two year fellowship in sports medicine and shoulder surgery at the Hospital for Special Surgery, New York. During this time he gained a National Institutes of Health First Award, an American Orthopaedic Association North American Travelling Fellowship and was a team physician for the New York Giants.

Dr. Murrell is now Chief of the Sports Medicine and Shoulder Service and Director of the Orthopaedic Research Institute at the University of New South Wales, Sydney Australia. He specializes in shoulder surgery and has a special interest in arthroscopic methods to repair and restore damaged ligaments and tendons.

barry p. simmons, md
Barry P. Simmons, MD is the Chief of the Hand and Upper Extremity Service at Brigham & Women’s Hospital, Boston, MA. He is responsible for the education of the residents of the Combined Harvard Orthopaedic program. He also holds the academic appointment of Associate Clinical Professor of Orthopaedic Surgery, Harvard Medical School.

Through his leadership position in the American Society for Surgery of the Hand, the Academic Orthopaedic Society and, especially the Council of Musculoskeletal Specialties, Dr. Simmons has made significant administrative contributions to academics. Dr. Simmons’ major interest and expertise is in diseases and injuries affecting the hand and upper extremity. He has authored several chapters and scientific papers about disorders of the hand and upper extremity in the pediatric age group.

Dr. Simmons received his MD degree from Columbia University in 1965 and completed his surgical internship at Tufts New England Medical Center and residency at the University of California at San Francisco School of Medicine. He completed his fellowship at the University of Paris, France, and has board certification in orthopedics since 1975 and in hand surgery since 1989.

lee s. simon, md
Dr. Simon is an Associate Clinical Professor of Medicine, Harvard Medical School and a practicing rheumatologist at the Beth Israel Deaconess Medical Center in Boston, MA. Dr. Simon has had a long history of involvement with the Food & Drug Administration (FDA), starting as a Consultant for DDMAC in 1992, progressing to a Member of the Over the Counter Advisory Committee in 1994, Membership of the Orthopedic Device Advisory Committee and GI Advisory Committee in 1997 and 1998, and culminating with his appointment as Division Director, Analgesic, Anti-inflammatory, Ophthalmologic Drug Products from 2001 to 2003. As Division Director, he lead a group of over 30 pharmaco-toxicologists, physicians, biostat experts, clinical pharmacologists,and other support staff, all involved in the design and study of all potential therapeutic drugs within his area of expertise.

Dr. Simon has a research interest in the clinical utility of non-steroidal anti-inflammatory drugs. He has produced about 30 review papers, as well as four original papers on the actions, effectiveness and toxicity of the NSAIDs. He played a key role in the development of new COX-2 specific inhibitors. He is on the Steering Committee of the International Study Group on COX-2, and is co-chair of the American Pain Society Algorithm Development Committee for the treatment of chronic pain in arthritis.

Dr. Simon received his medical degree from the University of Maryland, completed his internship and residency in internal medicine at the Johns Hopkins Hospital, and trained in the arthritis unit of the Massachusetts General Hospital and Harvard Medical School. He has been a member of the boards of directors of the American College of Rheumatology and the American College of Rheumatology Research and Education Foundation, and has served on the scientific advisory board of the National Osteoporosis Foundation. He has received numerous awards for his accomplishments, and last year received the S.L.E. Foundation’s Scientific Leadership Award.

robert e. baldini, mba (special advisor to the board)
Mr. Baldini has served as Vice Chairman of the Board and senior marketing consultant of Kos Pharmaceuticals since 1996, and as Kos’s Chief Sales and Marketing Officer from 1998 until 2001. In these positions, Mr. Baldini served as an executive officer and oversaw all sales and marketing functions including sales strategies, product positioning and marketing budgets. He was also responsible for guiding the creation of the company’s sales and marketing departments and for the product launch of Niaspan. Outside of Kos, Mr. Baldini served as a director of Ascent Pediatrics, Inc. He served with Key Pharmaceuticals from 1982 to 1986 as Senior Vice President of Sales and Marketing. Following its acquisition by Schering-Plough, he continued with the Key Pharmaceuticals Division of Schering-Plough until 1995, last serving as its President.

Mr. Baldini’s more than 50 years of pharmaceutical industry experience include senior management positions at Key, Pfizer, and Ciba-Geigy, and he has been involved in the development, launch and management of several innovative, best-selling drug delivery products, including K-dor and Imdor along with the Nitro-dor transdermal nitroglycerin patch. Mr Baldini holds a BS degree from Seton Hall University and an MBA from New York University. He is currently a member of the Seton Hall University Board of Regents.

susan l. michlovitz, pt, Ph.D., cht (special advisor to the board)
Dr. Michlovitz is an expert in upper limb orthopedic pathologies. She is an Adjunct Professor at Temple University in Philadelphia, PA, Professor at Rocky Mountain University of Health Sciences at Provo, Utah, and clinician at Finger Lakes Physical Therapy, PC in Ithaca, NY. Her areas of teaching interest are examination and interventions for musculoskeletal dysfunctions, clinical anatomy and biomechanics and evidence-based practice. She was a 2003 recipient of the Vargus Hand Therapy Teaching Award and a Clinician/Teacher of the Year Award in 2003 from the American Association for Hand Surgery. Her textbook has a been a standard in physical therapist education and is presently in its 4th edition (Michlovitz SL, Nolan TP, eds. Modalities for Therapeutic Intervention, FA Davis Company, Philadelphia, 2005).

Dr. Michlovitz’s research interests are in clinical outcomes and in effectiveness of physical therapy intervention following elbow, wrist and hand injuries. She has authored numerous chapters and articles in the areas of hand therapy and physical agent modalities. Her research has focused on assessment of recovery from hand and wrist injuries and disorders and assessment of surgical and therapy interventions. Her current research area is related to examining reliability, validity and responsiveness of upper extremity assessment tools including the push-off test and Patient Specific Functional Scale. Dr. Michlovitz is on the Editorial Advisory Board of the Journal of Hand Therapy and the Editorial Board of Techniques in Hand and Upper Extremity Surgery. In 2003 she was awarded the "Hand Therapy Paper Award" at the American Association for Hand Surgery (AAHS) Annual Meeting. She is also on the Board of Governors of the Hand Surgery Endowment of the American Association for Hand Surgery.

Dr. Michlovitz obtained her B.S. from Case Western Reserve University, Certificate in Physical Therapy from the University of Pennsylvania, MS in Physiology from Temple Medical School and a Ph.D. in Orthopedic Physical Therapy from Hahnemann University.

next >